Madappa Kundranda
Hematology-Oncology · Gilbert, AZNPI 1760686521
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,331 of the $70,946 with a category attached, or 69.5%. 18 manufacturers reported payments, led by Bayer at 33.7% of the total. Reporting peaked in 2019 at $23,544 and has fallen 80.4% since, to $4,621 in 2025.
Across 77 payments — averaging $921.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$24K
- E.r. Squibb & Sons, L.L.C.$10K
- Amgen$9K
- US Endoscopy$9K
- Agios Pharmaceuticals, Inc.$4K
- Boehringer Ingelheim International GmbH$4K
- plus $11K from 12 others
Across 446 payments — averaging $6117.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$586K
- Chugai Pharmaceutical Co., Ltd.$532K
- Genentech, Inc.$501K
- Taiho Oncology, Inc.$338K
- Beigene, Ltd.$229K
- EMD Serono, Inc.$173K
- plus $370K from 9 others
What the payments were for
- Consulting fees$49,33170%
- Speaking & faculty fees$16,67023%
- Travel & lodging$2,9374%
- Food & beverage$1,9903%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 19 | $23,907 |
| E.r. Squibb & Sons, L.L.C. | 12 | $9,804 |
| Amgen | 5 | $9,300 |
| US Endoscopy | 8 | $9,075 |
| Agios Pharmaceuticals, Inc. | 7 | $3,872 |
| Boehringer Ingelheim International GmbH | 1 | $3,700 |
| Boston Scientific | 2 | $3,250 |
| Astrazeneca UK Limited | 1 | $2,055 |
| Beone Medicines USA, Inc. | 1 | $1,950 |
| Merck | 10 | $1,493 |
| Exelixis Inc. | 1 | $1,320 |
| AstraZeneca | 1 | $685 |
| Genentech USA, Inc. | 2 | $301 |
| Pfizer | 1 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $53 |
| Eisai Inc. | 3 | $46 |
| Caris MPI, Inc. | 1 | $34 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 21 | $354 |
| Prochlorperazine Maleate | 18 | $350 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Gilbert
- Navjeet GandhokPeoria$19K
- Amol RakkarGlendale$18K
- Alejandro Recio BoilesTucson$5K
- Valerie IsraelLake Havasu City$4K
- James ChoiGlendale$4K
- Madhuri KadiyalaChandler$865
- Srivyshnavi NarraSun City$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.